| 1 |
31129789 | Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole. | 2019 Dec |
1 |
| 2 |
31204932 | [Reversal Effect of Pioglitazone on Multidrug Resistance in K562/ADR Cells and Its Mechanism]. | 2019 Jun |
1 |
| 3 |
29545948 | The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects. | 2018 Apr |
1 |
| 4 |
29663414 | Bidirectional Pharmacokinetic Interaction Between Amodiaquine and Pioglitazone in Healthy Subjects. | 2018 Aug |
3 |
| 5 |
27599706 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. | 2017 Apr |
1 |
| 6 |
28099407 | Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. | 2017 Apr |
2 |
| 7 |
28340451 | The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. | 2017 Apr |
2 |
| 8 |
29174535 | Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human. | 2017 Dec |
2 |
| 9 |
27163495 | Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies. | 2016 May |
2 |
| 10 |
27260150 | Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. | 2016 Aug |
3 |
| 11 |
27457785 | Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. | 2016 Oct |
2 |
| 12 |
27504016 | In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. | 2016 Oct |
1 |
| 13 |
26296069 | Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone. | 2015 Dec |
1 |
| 14 |
22625877 | Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. | 2013 Jan |
8 |
| 15 |
23370354 | Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. | 2013 |
7 |
| 16 |
23712614 | Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. | 2013 Sep |
3 |
| 17 |
24324437 | Current clinical evidence on pioglitazone pharmacogenomics. | 2013 |
1 |
| 18 |
20875371 | Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. | 2010 Oct |
1 |
| 19 |
19614891 | The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. | 2009 Dec |
9 |
| 20 |
19761371 | Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. | 2009 Sep |
2 |
| 21 |
17901929 | Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. | 2008 May |
1 |
| 22 |
17913794 | Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. | 2008 Jan |
7 |
| 23 |
17201456 | Pharmacokinetic interactions with thiazolidinediones. | 2007 |
1 |
| 24 |
16299161 | Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. | 2006 Jan |
1 |
| 25 |
16390353 | Effect of rifampicin on the pharmacokinetics of pioglitazone. | 2006 Jan |
2 |
| 26 |
16447051 | Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. | 2006 Mar |
3 |
| 27 |
16670899 | Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. | 2006 Jul |
1 |
| 28 |
16867170 | Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. | 2006 Jul |
7 |
| 29 |
17214065 | The pharmacokinetics of pioglitazone in Thai healthy subjects. | 2006 Dec |
1 |
| 30 |
15900286 | Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. | 2005 May |
3 |
| 31 |
16283275 | Effect of gemfibrozil on the pharmacokinetics of pioglitazone. | 2005 Dec |
1 |
| 32 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
2 |
| 33 |
11921435 | Differentiating members of the thiazolidinedione class: a focus on safety. | 2002 Mar-Apr |
2 |